Veracyte shares rose to $49.94, crossing above the average analyst 12-month target price of $48.80. The article is primarily a technical/analyst commentary item, noting the stock has reached consensus price target levels rather than reporting new operating or financial results. Market impact is likely limited, though it may prompt analyst rating changes or short-term trading interest.
Veracyte shares rose to $49.94, crossing above the average analyst 12-month target price of $48.80. The article is primarily a technical/analyst commentary item, noting the stock has reached consensus price target levels rather than reporting new operating or financial results. Market impact is likely limited, though it may prompt analyst rating changes or short-term trading interest.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
